Antiphospholipid antibody syndrom;Syndrome des antiphospholipides

Hematologie

Volumn 12, Issue 2, 2006, Pages 101-110

  Godeau, Bertrand ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Anticoagulant; Antiphospholipid antibody; APS; Thrombosis

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; STEROID; VITAMIN K GROUP;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; CLINICAL FEATURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIFESPAN; MICROVASCULATURE; NERVOUS SYSTEM; PATHOPHYSIOLOGY; PREGNANCY OUTCOME; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VEIN THROMBOSIS;

EID: 33744815602     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Piette JC, Fois E, Costedoat-Chalumeau N. Syndrome des antiphospholipides. In: Godeau P, Herson S, Piette JC, et al., eds. Traité de Médecine, 4e édition. Paris: Flammarion 2004: 148-54.
2. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 340: 752-03.
3. Galli M. Antiphospholipid antibodies and thrombosis: do test patterns identify the patients' risk? Thromb Res 2004; 114: 597-601.
4. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome Arthritis Rheum 1999; 42: 309-11.
5. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
6. de Groot PG, Derksen RHWM. Antiphospholipid antibodies: update on detection, pathophysiology, and treatment. Curr Opin Hematol 2004; 11: 166-9.
7. Akimoto T, Akama T, Saitoh M, Kono I, Sumida T. Antiprothrombin autoantibodies in severe preeclampsia and abortion. Am J Med 2001; 110: 188-91.
8. Rand JH. Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome. J Autoimmun 2000; 15: 107-11.
9. Yasuda S, Atsumi T, Ieko M, et al. Nicked beta2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. Blood 2004; 103: 3766-72.
10. Merten M, Motamedy S, Ramamurthy S, Arnett FC, Thiagarajan P. Sulfatides: targets for anti-phospholipid antibodies. Circulation 2003; 108: 2082-7.
11. Meroni PL, Raschi E, Camera M, et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestation of the syndrome. J Autoimmun 2000; 15: 237-40.
12. Roubey RAS. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum 2003; 48: 3004-8.
13. Cervera R, Piette JC, Font J, et al., Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27.
14. Brey RL. Management of the neurological manifestations of APS - what do the trials tell us? Thromb Res 2004; 114: 489-99.
15. Piette JC, Amoura Z, Wechsler B. Syndromes des antiphospholipides. In: Déchy H, Wechsler B, Hausfaler P, Rancurel G, Piette JC, eds. Atteintes neurologiques au cours des maladies systémiques. Paris: Flammarion Médecine-Sciences, 2003: 148-53.
16. Frances C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine 1999; 78: 209-19.
17. Chapman J. The interface of multiple sclerosis and antiphospholipid antibodies. Thromb Res 2004; 114: 477-81.
18. Cuadrado MJ, Khamastha MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurological manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine 2000; 79: 57-68.
19. Nochy D, Daugas E, Le Thi Huong D, Piette JC, Hil G. Kidney involvement in the antiphospholipid syndrome. J Autoimmun 2000; 15: 127-32.
20. Espinosa G, Santos E, Cervera R, et al. Adrenal involvement in the antiphospholipid syndrome. Clinical and immunologic characteristics of 86 patients Medicine 2003; 82: 106-18.
21. Laraki R, Blétry O, Wechsler B, Piette JC, de Zuttere D, Godeau P. Coeur et anticorps anntiphospholipides. Expérience personnelle et revue de la littérature. Rev Med Interne 1996; 17: 46-57.
22. Cervera R. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res 2004; 114: 501-7.
23. Francès C, Piette JC. Dermatologic manifestations in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, Shoenfeld Y, eds. The antiphospholipid syndrome II: Autoimmune thrombosis. Amsterdam: Elsevier, 2002: 235-44.
24. Deane KD, West SG. Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review. Semin Arthritis Rheum 2005; 35: 154-65.
25. Asherson RA, Cervera R, Wells AU. Diffuse alveolar hemorrhage: a nonthrombotic antiphospholipid lung syndrome? Semin Arthitis Rheum 2005; 35: 138-42; (Editorial).
26. Krause I, Blank M, Fraser A, et al. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology 2005; 210: 749-54.
27. Godeau B, Piette JC, Fromont P, Intrator L, Schaeffer A, Bierling P. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol 1997; 98: 873-9.
28. Stasi R, Stipa E, Masi M, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994; 84: 4203-8.
29. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001; 98: 1760-4.
30. Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine 1998; 77: 195-207.
31. Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome. Arthritis Rheum 2003; 48: 3320-7.
32. Le Thi Thuong D, Tieulie N, Costedoat N, et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis 2005; 64: 273-8.
33. Amoura Z Costedoat-Chalumeau N, Veyradier A, et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum 2004; 50: 3260-4.
34. Ruiz-Irastorza G, Khamasta M, Hughes GRV. Treatment of pregnancy loss in Hughes syndrome: a critical update. Autoimmun Rev 2002; 1: 298-304.
35. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
36. Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med 2004; 164: 77-82.
37. Khamashta M, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995; 332: 993-7.
38. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
39. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-53.
40. Crowther MA, Wisloff F. Evidence based treatment of the antiphospholipid syndrome. II. Optimal anticoagulant therapy for thrombosis. Thromb Res 2005; 115: 3-8.
41. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-8.
42. Lockshin MD, Erkan D. Treatment of the antiphospholipid syndrome. N Engl J Med 2003; 349: 1177-9.
43. Levine SR and the APASS investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004; 291: 576-84.
44. Gatenby PA. Controversies in the antiphospholipid syndrome and stroke. Thromb Res 2004; 114: 483-8.
45. Cockerill KA, Iverson GA, Jones DS, Linnik MD. Therapeutic potential of toleragens in the management of antiphospholipid syndrome. BioDrugs 2004; 18: 297-305.
46. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phopsholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-7.